Investig Clin Urol.  2017 Jul;58(4):217-219. 10.4111/icu.2017.58.4.217.

Prostate cancer screening

• Eastham J

• KMID: 2410286
• DOI: http://doi.org/10.4111/icu.2017.58.4.217

Abstract

No abstract available.

MeSH Terms

Mass Screening*
Prostate*
Prostatic Neoplasms*

Reference

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017; 67:7–30.

2. Giri VN, Beebe-Dimmer JL. Familial prostate cancer. Semin Oncol. 2016; 43:560–565.

3. Bancroft EK, Page EC, Castro E, Lilja H, Vickers A, Sjoberg D, et al. Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study. Eur Urol. 2014; 66:489–499.

4. Park SY, Haiman CA, Cheng I, Park SL, Wilkens LR, Kolonel LN, et al. Racial/ethnic differences in lifestyle-related factors and prostate cancer risk: the Multiethnic Cohort Study. Cancer Causes Control. 2015; 26:1507–1515.

5. De Marzo AM, Marchi VL, Epstein JI, Nelson WG. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol. 1999; 155:1985–1992.

6. Carlsson S, Assel M, Sjoberg D, Ulmert D, Hugosson J, Lilja H, et al. Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study. BMJ. 2014; 348:g2296.

7. Draft recommendation statement. Prostate Cancer: screening [Internet]. Rockville, (MD): U.S. Preventive Services Task Force;2016. cited 2017 June 18. Available from: https://www.uspreventiveservicestaskforce.org/Page/Document/draft-recommendation-statement/prostate-cancer-screening1.